Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C13H11N3O4
CAS Number:
Molecular Weight:
273.24
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Pomalidomide, ≥98% (HPLC)
ligand
pomalidomide
Quality Level
assay
≥98% (HPLC)
form
powder
reaction suitability
reagent type: ligand
color
yellow
solubility
DMSO: ≥14 mg/mL
storage temp.
2-8°C
SMILES string
Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12
InChI
1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
InChI key
UVSMNLNDYGZFPF-UHFFFAOYSA-N
Gene Information
human ... CRBN(51185), CUL4A(8451), DDB1(1642), RBX1(9978)
Application
Pomalidomide has been used:
- to treat BV173 cells to study the role of proteolysis targeting chimera (PROTAC) compound, JQ1-CRBN, in inducing specific class-I major histocompatibility complex (MHC-I) peptides
- for apoptosis studies and intracellular calcium analysis
- as a fetal hemoglobin (HbF) agent to study the additive effect with UNC0638 on the levels of fetal hemoglobin expression in β-thalassemia/ variant hemoglobin E (HbE) erythroid progenitor cells
Biochem/physiol Actions
Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog.
Pomalidomide is an effective fetal hemoglobin (HbF) inducer that downregulates the key γ-globin repressors, SRY-box transcription factor 6 (SOX6), and BAF chromatin remodeling complex subunit (BCL11A).
Features and Benefits
This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Manh-Cuong Vo et al.
Frontiers in immunology, 9, 1798-1798 (2018-08-21)
We have previously shown that immunization with tumor antigen-loaded dendritic cells (DCs) and the immunomodulating drug, lenalidomide, synergistically potentiates the enhancing antitumor immunity in a myeloma mouse model. In this study, we investigated the immunogenicity of DCs combined with pomalidomide
Suzanne Lentzsch et al.
Cancer research, 62(8), 2300-2305 (2002-04-17)
Thalidomide has recently been shown to be useful in the treatment of multiple myeloma and may also be useful in the treatment of other hematological malignancies. We have identified a new derivative of thalidomide, S-3-[3-amino-phthalimido]-glutarimide (S-3APG) with dual activity against
Emma C Fink et al.
Blood, 132(14), 1535-1544 (2018-08-02)
Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective treatments for multiple myeloma and myelodysplastic syndrome with del(5q). These molecules lack activity in murine models, limiting investigation of their therapeutic activity or toxicity in vivo. Here, we report the
Global Trade Item Number
| SKU | GTIN |
|---|---|
| P0018-25MG | 04061833213193 |
| P0018-5MG | 04061834261841 |
